Tag
ZTS
3 articles
Zoetis Down 37% YTD: Pet Care Trade-Down Is Real, Not Priced In
Zoetis shares have collapsed as pet owners cut spending on premium treatments, yet hedge fund accumulation suggests Wall Street is missing the structural headwind.
Zoetis Rated Strong Sell Ahead of Earnings Miss
ZTS slides 2.22% to $71.40 as analysts project double-digit EPS decline and assign Zacks Rank #5; stock trades at 11.77x forward earnings.
Zoetis FDA Delay Is a Buying Opportunity, Not a Verdict
ZTS fell 8 percent after the FDA requested more data on its canine osteoarthritis vaccine, but the selloff overstates the damage to a dominant franchise